Protalix BioTherapeutics (PLX) EBIT (QoQ) (2010 - 2026)
Protalix BioTherapeutics (PLX) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.91% |
| Mar 31, 2026 | 553.97% |
| Dec 31, 2025 | -318.58% |
| Sep 30, 2025 | 81.83% |
| Jun 30, 2025 | 128.28% |
| Mar 31, 2025 | -157.50% |
| Dec 31, 2024 | 80.63% |
| Sep 30, 2024 | 264.44% |
| Jun 30, 2024 | 50.02% |
| Mar 31, 2024 | 13.52% |
| Dec 31, 2023 | -197.56% |
| Sep 30, 2023 | -109.24% |
| Jun 30, 2023 | 930.46% |
| Mar 31, 2023 | 1.44% |
| Dec 31, 2022 | 20.16% |
| Sep 30, 2022 | 43.43% |
| Jun 30, 2022 | -195.40% |
| Mar 31, 2022 | 67.23% |
| Dec 31, 2021 | -202.71% |
| Sep 30, 2021 | 79.43% |